Intellia Therapeutics Inc.

In News

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Intellia Therapeutics

Intellia Therapeutics - Oct 13, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Stocktwits - Oct 14, 2026

Intellia Therapeutics, Inc. (NTLA) options chain - Yahoo Finance Australia

Yahoo Finance Australia - Oct 17, 2026

Intellia Therapeutics names Jing Marantz as EVP and CMO - The Pharma Letter

The Pharma Letter - Oct 14, 2026

Intellia Therapeutics names Jing Marantz as chief medical officer - Investing.com

Investing.com - Oct 13, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I - TradingView

TradingView - Oct 12, 2026

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics - Aug 06, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Stocktwits - Oct 17, 2026

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics - Sep 08, 2026

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics - May 11, 2026

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - Intellia Therapeutics

Intellia Therapeutics - Sep 04, 2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics - Jun 13, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment